Onxeo has experienced a volatile 2017 mainly due to Livatag’s Phase III ReLive not meeting its primary endpoint. The out-licensing of Validive, fresh data from several preclinical studies with core assets – AsiDNA and belinostat combinations – were more positive recent developments. Although the share price halved after the disappointing ReLive data, the asset portfolio has been radically reshaped to focus on DNA break repair inhibition and epigenetics and Onxeo has cas
29 Nov 2017
Introducing platON; AsiDNA approaches Phase I
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Introducing platON; AsiDNA approaches Phase I
Valerio Therapeutics (ALVIO:PAR) | 0 0 0.0%
- Published:
29 Nov 2017 -
Author:
Dr Jonas Peciulis -
Pages:
15
Onxeo has experienced a volatile 2017 mainly due to Livatag’s Phase III ReLive not meeting its primary endpoint. The out-licensing of Validive, fresh data from several preclinical studies with core assets – AsiDNA and belinostat combinations – were more positive recent developments. Although the share price halved after the disappointing ReLive data, the asset portfolio has been radically reshaped to focus on DNA break repair inhibition and epigenetics and Onxeo has cas